Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients

被引:12
作者
Grieco, A
Castellano, R
Matera, A
Marcoccia, S
Di Rocco, P
Ragazzoni, E
Vecchio, FM
Gasbarrini, G
机构
[1] Univ Cattolica Sacro Cuore, Dept Internal Med & Geriatr, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Pharmacol, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Fac Med, Dept Pathol, I-00168 Rome, Italy
关键词
antipyrine clearance; chronic active hepatitis; cirrhosis; hepatocellular carcinoma; liver cancer; liver metastases;
D O I
10.1111/j.1440-1746.1998.tb00668.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Antipyrine metabolism is widely used as an index of the drug-metabolizing reserve of the liver. It is well known that metabolism of this drug is impaired in subjects with acute hepatitis or cirrhosis, but conflicting data have been reported regarding patients with chronic postinfectious hepatitis or liver cancer. We studied conventional liver-function parameters and antipyrine metabolism (antipyrine per o.s. 18 mg/kg) in 518 subjects. One hundred and one patients had liver metastases (various primaries). Based on the number and size of lesions, the hepatic involvement was considered minimal in 47 and massive in 54 (groups B1 and B2, respectively). One hundred and two had chronic active hepatitis (CAH); 51 patients with histological evidence of fibrosis/early cirrhosis and 51 patients were without histological evidence of fibrosis/early cirrhosis. Ninety-two had histologically confirmed cirrhosis (group D), and the remaining 120 had cirrhosis and hepatocellular carcinoma (group E). The control group was composed of 103 subjects with healthy livers (group A). Antipyrine clearance (AP Cl) in CAH patients with fibrosis (0.246 +/- 0.98 ml/min per kg) was similar to that observed in patients with cirrhosis (0.223 +/- 0.148 mL/min per kg), and both values were significantly lower than that found in CAH patients without fibrosis (0.406 +/- 0.159 mL/min per kg, P < 0.01). Antipyrine clearance in patients with liver metastases (0.426 +/- 0.174 mL/min per kg) was similar to that of the healthy group (0.489 +/- 0.210 mL/min per kg). Cirrhotics and cirrhotics with hepatocellular carcinoma (HCC) presented similar degrees of impairment. Antipyrine clearance was positively correlated with serum albumin (r(2) = 0.10, P = 0.01) and prothrombin time (r(2) = 0.129, P < 0.01) in all groups, except those with liver metastases. In patients with CAH, the presence of fibrosis/cirrhosis is associated with impaired antipyrine metabolism. The lack of impairment in groups with liver metastases suggests that the functional hepatic reserve is maintained even in the presence of massive neoplastic invasion.
引用
收藏
页码:460 / 466
页数:7
相关论文
共 50 条
  • [31] Management of COVID-19 patients with chronic liver diseases and liver transplants
    Hu, Xinyu
    Sun, Longyan
    Guo, Zhaoyang
    Wu, Chao
    Yu, Xin
    Li, Jie
    ANNALS OF HEPATOLOGY, 2022, 27 (01)
  • [32] Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases
    Silva, Telma E.
    Ronsoni, Marcelo F.
    Schiavon, Leonardo L.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2018, 12 (03) : 431 - 440
  • [33] Thrombin Generation in Chronic Liver Diseases-A Pilot Study
    Vecerzan, Liliana
    Olteanu, Ariela
    Maniu, Ionela
    Boicean, Adrian
    Cipaian, Calin Remus
    Dura, Horatiu
    Fleca, Sorin Radu
    Mihaila, Romeo Gabriel
    HEALTHCARE, 2021, 9 (05)
  • [34] Surgical Clearance for the Patient with Chronic Liver Disease
    Muir, Andrew J.
    CLINICS IN LIVER DISEASE, 2012, 16 (02) : 421 - +
  • [35] Chronic cholestatic liver diseases
    Waldum, H. L.
    Bjornsson, E. S.
    Brenna, E.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (6-7) : 788 - 788
  • [36] Alcohol's Effect on Other Chronic Liver Diseases
    Lee, Maximilian
    Kowdley, Kris V.
    CLINICS IN LIVER DISEASE, 2012, 16 (04) : 827 - +
  • [37] Role of Scavenger Receptors in the Pathophysiology of Chronic Liver Diseases
    Armengol, Carolina
    Bartoli, Ramon
    Sanjurjo, Lucia
    Serra, Isabel
    Amezaga, Nuria
    Sala, Margarita
    Sarrias, Maria-Rosa
    CRITICAL REVIEWS IN IMMUNOLOGY, 2013, 33 (01) : 57 - 96
  • [38] Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis
    Wojcicki, J
    Kozlowski, K
    Drozdzik, M
    Wojcicki, M
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2002, 27 (04) : 243 - 247
  • [39] Contrast-Enhanced Ultrasound in Chronic Liver Diseases
    Spann, Stephanie
    Fetzer, David T.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2021, 29 (03) : 291 - 304
  • [40] Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis
    J. Wojcicki
    K. Kozlowski
    M. Drozdzik
    M. Wojcicki
    European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27 : 243 - 247